Literature DB >> 28704213

Menstrual pad, a cervical cancer screening tool, a population-based study in rural India.

Atul Budukh1, Vrushali Palayekar2, Amita Maheshwari1, Kedar Deodhar1, Pallavi Purwar1, Sonali Bagal1, Ashok Vadigoppula2, Manoj Lokhande3, Nandkumar Panse3, Rajesh Dikshit1, Rajendra Badwe1.   

Abstract

In the rural areas of India, women generally use a piece of old cloth as a menstrual device. The aim of this study was to detect human papilloma virus (HPV) from menstrual blood on the menstrual pad and assess whether this could be a useful screening tool for cervical cancer. In Jamkhed area of rural Maharashtra, (population A), we collected menstrual pads from women who provided consent in the 30-50 year age group. The women who had provided menstrual pads underwent HC2 testing. We standardized the method for extracting DNA by PCR from the menstrual pad. The women who tested HPV positive, on the basis of HC2/PCR testing, underwent colposcopy. In the rural population of Pune area of Maharashtra state (population B), menstrual pads were collected. HPV was tested using the PCR method. HPV-positive women and a few HPV-negative women, selected randomly, underwent colposcopy and HC2 testing. In population A, 164 women provided their used menstrual pads and also underwent an HC2 screening test. Of these, six (3.2%) cases were reported as HPV positive. In population B, 365 women provided their used menstrual pads for HPV testing, of which 18 (4.9%) cases were diagnosed as HPV positive. The women who tested HPV positive, on the basis of PCR testing, and 10% randomly selected HPV-negative cases (37) and 18 women who voluntary requested testing underwent colposcopy and HC2 testing. The sensitivity of menstrual pad HPV testing compared with gold standard HC2 testing was 83% [95% confidence interval (CI): 0.47-0.97], 67% (95% CI: 0.30-0.91) and specificity was 99% (95% CI: 0.96-0.99), 88% (95% CI: 0.77-0.94) in population A and population B, respectively. The sensitivity of diagnosing CIN lesion was 83% (95% CI: 0.44-0.97) and specificity was 95% (95% CI: 0.91-0.97). On the basis of the sensitivity and specificity results, and the completely noninvasive, simple and convenient method of detecting HPV, menstrual pad might be considered a cervical cancer screening tool in rural Indian women.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 28704213     DOI: 10.1097/CEJ.0000000000000387

Source DB:  PubMed          Journal:  Eur J Cancer Prev        ISSN: 0959-8278            Impact factor:   2.497


  5 in total

1.  Knockdown of BRCC3 exerts an anti‑tumor effect on cervical cancer in vitro.

Authors:  Feifang Zhang; Qun Zhou
Journal:  Mol Med Rep       Date:  2018-09-26       Impact factor: 2.952

Review 2.  Contribution of Tata Memorial Centre, India, to cervical cancer care: Journey of two decades.

Authors:  Anuj Kumar; Supriya Chopra; Sudeep Gupta
Journal:  Indian J Med Res       Date:  2021-08       Impact factor: 5.274

Review 3.  Diagnostic accuracy of menstrual blood for human papillomavirus detection in cervical cancer screening: a systematic review.

Authors:  Priyal Chakravarti; Amita Maheshwari; Shweta Tahlan; Prithviraj Kadam; Sonali Bagal; Suvarna Gore; Nandkumar Panse; Kedar Deodhar; Pankaj Chaturvedi; Rajesh Dikshit; Atul Budukh
Journal:  Ecancermedicalscience       Date:  2022-07-14

4.  Determinants of completion of cancer directed treatment: an experience from a rural cancer centre, Sangrur, Punjab state, India.

Authors:  Atul M Budukh; Debashish Chaudhary; Sankalp Sancheti; Tapas Dora; Alok Kumar Goel; Anshul Singla; Akash Sali; Shraddha Shinde; Kuldeep Singh Chauhan; Prithviraj Kadam; Raza Mohammad; Rakesh Kapoor; Pankaj Chaturvedi; Rajesh P Dikshit; Rajendra A Badwe
Journal:  Ecancermedicalscience       Date:  2021-11-01

5.  Feasibility and Accuracy of Menstrual Blood Testing for High-risk Human Papillomavirus Detection With Capture Sequencing.

Authors:  Jingjing Zhang; Xun Tian; Ye Chen; Sisi Huang; Zifeng Cui; Rui Tian; Zhen Zeng; Wenjia Liang; Qifen Gong; Ronghua Shang; Zheng Hu; Chen Cao
Journal:  JAMA Netw Open       Date:  2021-12-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.